T cell immunoglobulin domain and mucin domain-3 as an emerging target for immunotherapy in cancer management

References

• VeselyMDKershawMHSchreiberRDSmythMJNatural innate and adaptive immunity to cancerAnnu Rev Immunol20112923527121219185
   PubMed Web of Science ®Google Scholar
• DunnGPOldLJSchreiberRDThe three Es of cancer immunoeditingAnnu Rev Immunol20042232936015032581
   PubMed Web of Science ®Google Scholar
• SmythMJDunnGPSchreiberRDCancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicityAdv Immunol20069015016730260
   PubMed Web of Science ®Google Scholar
• KhongHTRestifoNPNatural selection of tumor variants in the generation of “tumor escape” phenotypesNat Immunol2002311999100512407407
   PubMed Web of Science ®Google Scholar
• FlavellRASanjabiSWrzesinskiSHLicona-LimónPThe polarization of immune cells in the tumour environment by TGFbetaNat Rev Immunol201010855456720616810
   PubMed Web of Science ®Google Scholar
• KatzJBMullerAJPrendergastGCIndoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escapeImmunol Rev200822220622118364004
   PubMed Web of Science ®Google Scholar
• RabinovichGACrociDORegulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancerImmunity201236332233522444630
   PubMed Web of Science ®Google Scholar
• NishikawaHSakaguchiSRegulatory T cells in tumor immunityInt J Cancer2010127475976720518016
   PubMed Web of Science ®Google Scholar
• KuraishyAKarinMGrivennikovSITumor promotion via injury- and death-induced inflammationImmunity201135446747722035839
   PubMed Web of Science ®Google Scholar
• DeNardoDGJohanssonMCoussensLMImmune cells as mediators of solid tumor metastasisCancer Metastasis Rev2008271111818066650
   PubMed Web of Science ®Google Scholar
• DrakeCGJaffeeEPardollDMMechanisms of immune evasion by tumorsAdv Immunol200690518116730261
   PubMed Web of Science ®Google Scholar
• RosenbergSAYangJCRestifoNPCancer immunotherapy: moving beyond current vaccinesNat Med200410990991515340416
   PubMed Web of Science ®Google Scholar
• GalluzziLSenovillaLZitvogelLKroemerGThe secret ally: immunostimulation by anticancer drugsNat Rev Drug Discov201211321523322301798
   PubMed Web of Science ®Google Scholar
• LakeRARobinsonBWImmunotherapy and chemotherapy – a practical partnershipNat Rev Cancer20055539740515864281
   PubMed Web of Science ®Google Scholar
• MonneyLSabatosCAGagliaJLTh1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune diseaseNature2002415687153654111823861
   PubMed Web of Science ®Google Scholar
• SantiagoCBallesterosATamiCMartínez-MuñozLKaplanGGCasasnovasJMStructures of T Cell immunoglobulin mucin receptors 1 and 2 reveal mechanisms for regulation of immune responses by the TIM receptor familyImmunity200726329931017363299
   PubMed Web of Science ®Google Scholar
• CaoEZangXRamagopalUAT cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surfaceImmunity200726331132117363302
   PubMed Web of Science ®Google Scholar
• NakayamaMAkibaHTakedaKTim-3 mediates phagocytosis of apoptotic cells and cross-presentationBlood2009113163821383019224762
   PubMed Web of Science ®Google Scholar
• DeKruyffRHBuXBallesterosAT cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cellsJ Immunol201018441918193020083673
   PubMed Web of Science ®Google Scholar
• ZhuCAndersonACSchubartAThe Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunityNat Immunol20056121245125216286920
   PubMed Web of Science ®Google Scholar
• RangachariMZhuCSakuishiKBat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustionNat Med20121891394140022863785
   PubMed Web of Science ®Google Scholar
• YangZZGroteDMZiesmerSCIL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphomaJ Clin Invest201212241271128222426209
   PubMed Web of Science ®Google Scholar
• NdhlovuLCLopez-VergèsSBarbourJDTim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicityBlood2012119163734374322383801
   PubMed Web of Science ®Google Scholar
• GleasonMKLenvikTRMcCullarVTim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9Blood2012119133064307222323453
   PubMed Web of Science ®Google Scholar
• AndersonACAndersonDEBregoliLPromotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cellsScience200731858531141114318006747
   PubMed Web of Science ®Google Scholar
• ChibaSBaghdadiMAkibaHTumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1Nat Immunol201213983284222842346
   PubMed Web of Science ®Google Scholar
• FourcadeJSunZBenallaouaMUpregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patientsJ Exp Med2010207102175218620819923
   PubMed Web of Science ®Google Scholar
• SakuishiKApetohLSullivanJMBlazarBRKuchrooVKAndersonACTargeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityJ Exp Med2010207102187219420819927
   PubMed Web of Science ®Google Scholar
• YanJZhangYZhangJPLiangJLiLZhengLTim-3 expression defines regulatory T cells in human tumorsPLoS One201383e5800623526963
   PubMed Web of Science ®Google Scholar
• HayakawaYSmythMJInnate immune recognition and suppression of tumorsAdv Cancer Res20069529332216860661
   PubMed Web of Science ®Google Scholar
• TianJAvalosAMMaoSYToll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGENat Immunol20078548749617417641
   PubMed Web of Science ®Google Scholar
• YanaiHBanTWangZHMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responsesNature200946272699910319890330
   PubMed Web of Science ®Google Scholar
• BaiJLiXTongDShiWSongHLiQT-cell immunoglobulin-and mucin-domain-containing molecule 3 gene polymorphisms and prognosis of non-small-cell lung cancerTumour Biol201334280580923359271
   PubMedGoogle Scholar
• YuanJJiangBZhaoHHuangQPrognostic implication of TIM-3 in clear cell renal cell carcinomaNeoplasia Epub9202013
   Google Scholar
• MellmanICoukosGDranoffGCancer immunotherapy comes of ageNature2011480737848048922193102
   PubMed Web of Science ®Google Scholar
• SharmaPWagnerKWolchokJDAllisonJPNovel cancer immunotherapy agents with survival benefit: recent successes and next stepsNat Rev Cancer2011111180581222020206
   PubMed Web of Science ®Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med2012366262455246522658128
   PubMed Web of Science ®Google Scholar
• WolchokJDKlugerHCallahanMKNivolumab plus ipilimumab in advanced melanomaN Engl J Med2013369212213323724867
   PubMed Web of Science ®Google Scholar
• BeattyGLChioreanEGFishmanMPCD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humansScience201133160241612161621436454
   PubMed Web of Science ®Google Scholar
• PorterDLLevineBLKalosMBaggAJuneCHChimeric antigen receptor-modified T cells in chronic lymphoid leukemiaN Engl J Med2011365872573321830940
   PubMed Web of Science ®Google Scholar
• KalosMJuneCHAdoptive T cell transfer for cancer immunotherapy in the era of synthetic biologyImmunity2013391496023890063
   PubMed Web of Science ®Google Scholar
• WeinbergADMorrisNPKovacsovics-BankowskiMUrbaWJCurtiBDScience gone translational: the OX40 agonist storyImmunol Rev2011244121823122017441
   PubMed Web of Science ®Google Scholar
• LynchDHThe promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancerImmunol Rev200822227728618364008
   PubMed Web of Science ®Google Scholar
• SchaerDACohenADWolchokJDAnti-GITR antibodies – potential clinical applications for tumor immunotherapyCurr Opin Investig Drugs2010111213781386
   PubMed Web of Science ®Google Scholar
• NgiowSFvon ScheidtBAkibaHYagitaHTengMWSmythMJAnti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumorsCancer Res201171103540355121430066
   PubMed Web of Science ®Google Scholar
• ZhouQMungerMEVeenstraRGCoexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemiaBlood2011117174501451021385853
   PubMed Web of Science ®Google Scholar
• BaghdadiMNagaoHYoshiyamaHCombined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomasCancer Immunol Immunother201362462963723143694
   PubMed Web of Science ®Google Scholar
• KryskoDVGargADKaczmarekAKryskoOAgostinisPVandenabeelePImmunogenic cell death and DAMPs in cancer therapyNat Rev Cancer2012121286087523151605
   PubMed Web of Science ®Google Scholar
• IwasakiAMedzhitovRRegulation of adaptive immunity by the innate immune systemScience2010327596329129520075244
   PubMed Web of Science ®Google Scholar
• JanMChaoMPChaACProspective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell markerProc Natl Acad Sci U S A2011108125009501421383193
   PubMed Web of Science ®Google Scholar
• KikushigeYShimaTTakayanagiSTIM-3 is a promising target to selectively kill acute myeloid leukemia stem cellsCell Stem Cell20107670871721112565
   PubMed Web of Science ®Google Scholar
• HuangXBaiXCaoYLymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasionJ Exp Med2010207350552020176801
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAHallmarks of cancer: the next generationCell2011144564667421376230
   PubMed Web of Science ®Google Scholar
• ZitvogelLGalluzziLSmythMJKroemerGMechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillanceImmunity2013391748823890065
   PubMed Web of Science ®Google Scholar
• KnightDANgiowSFLiMHost immunity contributes to the anti-melanoma activity of BRAF inhibitorsJ Clin Invest201312331371138123454771
   PubMed Web of Science ®Google Scholar